| Venetoclax and obinutuzumab in patients with CLL and coexisting conditions K Fischer, O Al-Sawaf, J Bahlo, AM Fink, M Tandon, M Dixon, S Robrecht, ... New England Journal of Medicine 380 (23), 2225-2236, 2019 | 863 | 2019 |
| Glofitamab for relapsed or refractory diffuse large B-cell lymphoma MJ Dickinson, C Carlo-Stella, F Morschhauser, E Bachy, P Corradini, ... New England Journal of Medicine 387 (24), 2220-2231, 2022 | 240 | 2022 |
| Venetoclax and obinutuzumab in chronic lymphocytic leukemia K Fischer, O Al-Sawaf, AM Fink, M Dixon, J Bahlo, S Warburton, TJ Kipps, ... Blood, The Journal of the American Society of Hematology 129 (19), 2702-2705, 2017 | 132 | 2017 |
| Bitopertin in negative symptoms of schizophrenia—results from the phase III FlashLyte and DayLyte studies D Bugarski-Kirola, T Blaettler, C Arango, WW Fleischhacker, G Garibaldi, ... Biological psychiatry 82 (1), 8-16, 2017 | 117 | 2017 |
| Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial A Davies, F Merli, B Mihaljević, S Mercadal, N Siritanaratkul, ... The Lancet Haematology 4 (6), e272-e282, 2017 | 102 | 2017 |
| Cytokine release in patients with CLL treated with obinutuzumab and possible relationship with infusion-related reactions CL Freeman, F Morschhauser, L Sehn, M Dixon, R Houghton, T Lamy, ... Blood, The Journal of the American Society of Hematology 126 (24), 2646-2649, 2015 | 79 | 2015 |
| Glofitamab step-up dosing induces high response rates in patients with hard-to-treat refractory or relapsed non-Hodgkin lymphoma M Hutchings, C Carlo-Stella, E Bachy, FC Offner, F Morschhauser, ... Blood 136, 46-48, 2020 | 52 | 2020 |
| Results of the safety run-in phase of CLL14 (BO25323): a prospective, open-label, multicenter randomized phase III trial to compare the efficacy and safety of obinutuzumab and … K Fischer, AM Fink, H Bishop, M Dixon, J Bahlo, MY Choi, R Weinkove, ... Blood 126 (23), 496, 2015 | 31 | 2015 |
| Role of CD20 expression and other pre-treatment risk factors in the development of infusion-related reactions in patients with CLL treated with obinutuzumab CL Freeman, M Dixon, R Houghton, KA Kreuzer, G Fingerle-Rowson, ... Leukemia 30 (8), 1763-1766, 2016 | 21 | 2016 |
| Efficacy and safety of adjunctive bitopertin (10 and 20mg) versus placebo in subjects with persistent predominant negative symptoms of schizophrenia treated with antipsychotics … T Blaettler, D Bugarski-Kirola, WW Fleischhacker, R Bressan, C Arango, ... Schizophrenia Research 1 (158), e2-e3, 2014 | 15 | 2014 |
| Cardiovascular safety of the glucagon‐like peptide‐1 receptor agonist taspoglutide in people with type 2 diabetes: an individual participant data meta‐analysis of randomized … SRK Seshasai, RL Bennett, JR Petrie, M Bengus, S Ekman, M Dixon, ... Diabetes, Obesity and Metabolism 17 (5), 505-510, 2015 | 14 | 2015 |
| Pattern of cytokine release in patients with chronic lymphocytic leukemia treated with obinutuzumab and possible relationship with development of infusion related reactions (IRR) CL Freeman, F Morschhauser, LH Sehn, M Dixon, R Houghton, T Lamy, ... Blood 124 (21), 4674, 2014 | 13 | 2014 |
| Risk factors associated with the development of infusion-related reactions in patients with chronic lymphocytic leukaemia treated with anti-CD20 monoclonal antibodies: analysis … CL Freeman, M Dixon, R Houghton, K Humphrey, G Fingerle-Rowson, ... Blood 124 (21), 3339, 2014 | 12 | 2014 |
| Safety and efficacy of venetoclax and obinutuzumab in patients with previously untreated chronic lymphocytic leukemia (CLL) and coexisting medical conditions: final results of … K Fischer, O Al-Sawaf, AM Fink, M Dixon, J Bahlo, S Warburton, TJ Kipps, ... Blood, The Journal of the American Society of Hematology 128 (22), 2054-2054, 2016 | 11 | 2016 |
| Effect of fixed-duration venetoclax plus obinutuzumab (VenG) on progression-free survival (PFS), and rates and duration of minimal residual disease negativity (MRD–) in … K Fischer, O Al-Sawaf, J Bahlo, AM Fink, M Tandon, M Dixon, S Robrecht, ... Journal of Clinical Oncology 37 (15_suppl), 7502-7502, 2019 | 7 | 2019 |
| Risk of Cytokine Release Syndrome with Glofitamab Is Predicted By an Updated Model with a Potential Clinical Application KV Komanduri, A Belousov, M Dixon, J Relf, M Tandon Blood 140 (Supplement 1), 9493-9495, 2022 | 4 | 2022 |
| Longer term efficacy and safety of subcutaneous compared with intravenous rituximab: updated results of the phase 3 SABRINA study AJ Davies, B Mihaljevic, S Mercadal, G Mihaylov, S Leppä, D Cotting, ... Blood 128 (22), 1103, 2016 | 4 | 2016 |
| Advancing drug development in pediatric oncology, a focus on cancer biology and targeted therapies: iMATRIX platform M Uguen, M Hilton, M Farid-Kapadia, A Datye, S Chohan, C Carlucci, ... Journal of Biopharmaceutical Statistics 33 (6), 800-811, 2023 | 2 | 2023 |
| Individual participant meta analysis of the cardiovascular safety of taspoglutide among individuals with diabetes KK Ray, R Bennett, J Petrie, M Bengus, S Ekman, M Dixon, M Herz, ... Circulation 126 (suppl_21), A15282-A15282, 2012 | 1 | 2012 |
| A Phase I/II Trial to Evaluate the Safety, Pharmacokinetics, and Efficacy of Glofitamab As Monotherapy and in Combination with R-ICE Chemoimmunotherapy in Children and Young … B Burkhardt, G Rossato, M Dixon, DJ Carlile, S Dmytrasz, J Wulff, ... Blood 142, 3096, 2023 | | 2023 |
